quinazolines has been researched along with topotecan in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (8.33) | 18.2507 |
| 2000's | 16 (44.44) | 29.6817 |
| 2010's | 16 (44.44) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Erlichman, C | 1 |
| McCann, J | 1 |
| Punt, CJ | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Pomatico, G; Tortora, G | 1 |
| Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW | 1 |
| Fleck, C; Hilger, R; Jurkutat, S; Karge, E; Merkel, U; Schimske, A; Schubert, J | 1 |
| Benson, A; Poplin, E; Vergote, I | 1 |
| Hayakawa, Y | 1 |
| Asada, S; Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Yanase, K | 1 |
| Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
| Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H | 1 |
| Bai, F; Houghton, PJ; Johnston, B; Leggas, M; Panetta, JC; Schuetz, JD; Sorrentino, B; Stewart, CF; Zhou, S; Zhuang, Y | 1 |
| Chianese, M; Cimmino, G; Laus, G; Penitente, R; Pepe, S; Prece, D; Quesada, P | 1 |
| Fraga, CH; Hagedorn, N; Hubbard, KE; Panetta, JC; Stewart, CF; Waters, CM; Zhuang, Y | 1 |
| Castellano, A; De Ioris, MA; De Laurentis, C; Dominici, C; Donfrancesco, A; Garganese, MC; Ilari, I; Jenkner, A; Milano, GM | 1 |
| Adjei, AA; Erlichman, C; Felten, SJ; Flatten, KS; Friedman, R; Gálvez-Peralta, M; Gilmer, TM; Jewell, RC; Kaufmann, SH; Koch, KM; Mandrekar, S; Molina, JR; Mullin, RJ; Reid, JM; Rubin, SD | 1 |
| Geoerger, B; Gerstenmeyer, A; Lagodny, J; Niemeyer, CM; Odenthal, E; Rössler, J; Vassal, G | 1 |
| Carcaboso, AM; Elmeliegy, MA; Hubbard, KE; Panetta, JC; Shen, J; Stewart, CF; Tagen, M; Waters, CM; Wynn, HG | 1 |
| Castellano, A; Cialfi, S; De Ioris, MA; De Laurentis, C; De Pasquale, MD; Dominici, C; Donfrancesco, A; Ilari, I; Jenkner, A; McDowell, HP | 1 |
| Calabrese, C; Carcaboso, AM; Elmeliegy, MA; Juel, SJ; Shen, J; Stewart, CF; Tracey, L; Waters, CM; Zhang, ZM | 1 |
| Dakhilm, SR; Haluska, P; Hartmann, LC; Keeney, GL; Moore, DF; Oberg, AL; Peethambaram, PP; Rowland, KM; Weroha, SJ; Ziegler, KL | 1 |
| Campone, M; Eierman, W; Greil, R; Kaufman, B; Lane, SR; Lin, NU; Rubin, SD; Steplewski, K; Winer, EP; Zembryki, D | 1 |
| Carloni, F; Castellani, C; Drudi, F; Lazzari-Agli, L; Sartori, S; Scarpi, E; Tassinari, D; Tombesi, P | 1 |
| Blanc-Fournier, C; Bourgeois, H; Briand, M; Clarisse, B; Fabbro, M; Joly, F; Krieger, S; Leconte, A; Lheureux, S; Lortholary, A; Pautier, P; Petit, T; Plantade, A; Richard, N; Selle, F; Vilquin, P; Weber, B | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Blakely, LJ; Schwartzberg, LS; Smiley, LM; Stewart, CF; Tagen, M; Tauer, KW | 1 |
| Downey, A; Levinson, B; Liebes, L; Muggia, F; Tiersten, A; Warner, E | 1 |
| Cao, KI; Kirova, YM | 1 |
| Fu, LW; He, JH; Huang, ZC; To, KK; Wang, F; Wang, XK; Xu, JH; Ye, S; Zhang, H | 1 |
| Carlomagno, C; Della Vittoria Scarpati, G; Ferrone, S; Fusciello, C; Leonardi, A; Pacelli, R; Pepe, S; Pepin, D; Poudel, R; Sabbatino, F; Somma, D | 1 |
| Fu, LW; Huang, LY; Huang, ZC; To, KK; Wang, F; Wang, XK; Xu, JH; Yang, K; Ye, S | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Chen, L; Chen, Z; Fu, L; Li, F; Wang, F; Wang, X; Zhang, W | 1 |
| Alqahtani, S; Ashby, CR; Bates, SE; Chen, ZS; Deng, T; Gupta, P; Kaddoumi, A; Lei, YX; Wang, YJ; Wurpel, JND; Zhang, GN; Zhang, YK | 1 |
| Gao, J; Li, X; Liu, Z; Teng, Y; Yin, P; Yu, P | 1 |
6 review(s) available for quinazolines and topotecan
| Article | Year |
|---|---|
Novel chemotherapeutic agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Mitomycin; Mitomycins; Paclitaxel; Pyrazoles; Quinazolines; Thiophenes; Topotecan | 1991 |
New drugs in the treatment of colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Topotecan; Trimetrexate; Uracil | 1998 |
ZD9331 in combination with topotecan: phase I and II experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Topotecan | 2003 |
Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Topotecan | 2012 |
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dacarbazine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Receptor, ErbB-2; Temozolomide; Thalidomide; Topoisomerase I Inhibitors; Topotecan; Trastuzumab; Vinblastine; Vinorelbine | 2014 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
7 trial(s) available for quinazolines and topotecan
| Article | Year |
|---|---|
ZD9331 in combination with topotecan: phase I and II experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Topotecan | 2003 |
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Female; Humans; In Vitro Techniques; Lapatinib; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasms; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2008 |
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Receptor, ErbB-2; Survival Rate; Topotecan | 2011 |
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Topotecan | 2011 |
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Female; Humans; Lapatinib; Metabolome; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Quinazolines; Recurrence; Risk Assessment; Topotecan; Treatment Outcome; Young Adult | 2012 |
Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Erlotinib Hydrochloride; Genotype; Humans; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Topotecan | 2014 |
Continuous-infusion topotecan and erlotinib: a study in topotecan-pretreated ovarian cancer assessing shed collagen epitopes as a marker of invasiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Collagen; Epitopes; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Neoplasm Invasiveness; Ovarian Neoplasms; Quinazolines; Topotecan | 2014 |
24 other study(ies) available for quinazolines and topotecan
| Article | Year |
|---|---|
Colon cancer: new drug options improve on 5-FU.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorouracil; Folic Acid Antagonists; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Tegafur; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1998 |
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Survival Rate; Taxoids; Thiophenes; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Carcinoma, Renal Cell; Cisplatin; Dexamethasone; Epidermal Growth Factor; Female; Glucocorticoids; Humans; Kidney; Kidney Neoplasms; Methotrexate; Quinazolines; Rats; Rats, Wistar; Thiophenes; Topotecan; Triiodothyronine | 2002 |
[Structure-activity relationship analysis].
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine | 2004 |
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrone; Gefitinib; Humans; Irinotecan; Neoplasm Proteins; Quinazolines; Topotecan | 2004 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan | 2006 |
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Topics: Absorption; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Interactions; Female; Gefitinib; Humans; LLC-PK1 Cells; Mice; Mice, Inbred C57BL; Mice, SCID; Mouth Mucosa; Quinazolines; Swine; Topotecan | 2006 |
Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Topics: Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Densitometry; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; Glioblastoma; Humans; In Situ Nick-End Labeling; Indicators and Reagents; Mutation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Signal Transduction; Topotecan; Tumor Suppressor Protein p53 | 2007 |
Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
Topics: Administration, Oral; Algorithms; Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood Proteins; Blood-Brain Barrier; Brain; Central Nervous System; Dose-Response Relationship, Drug; Extracellular Fluid; Female; Gefitinib; Immunohistochemistry; Injections, Intravenous; Mice; Mice, Inbred C57BL; Microdialysis; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Time Factors; Topotecan | 2006 |
Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Female; Gefitinib; Humans; Neuroblastoma; Quinazolines; Radionuclide Imaging; Recurrence; Topotecan; Treatment Outcome | 2007 |
EGFR inhibition using gefitinib is not active in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Blotting, Western; Cell Proliferation; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Mutation; Neuroblastoma; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan; Tumor Cells, Cultured | 2009 |
Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
Topics: Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Blood Proteins; Blood-Brain Barrier; Brain; Cell Line, Tumor; Gefitinib; Humans; Immunohistochemistry; Mice; Mice, Knockout; Microdialysis; Protein Binding; Quinazolines; Tissue Distribution; Topotecan | 2009 |
Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Pilot Projects; Prognosis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Salvage Therapy; Survival Rate; Topotecan; Treatment Outcome | 2010 |
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2010 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
Afatinib enhances the efficacy of conventional chemotherapeutic agents by eradicating cancer stem-like cells.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; DNA Methylation; Drug Synergism; Humans; Leukemia; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplastic Stem Cells; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Signal Transduction; Topotecan; Xenograft Model Antitumor Assays | 2014 |
Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Flow Cytometry; Glioblastoma; Humans; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Radiation, Ionizing; Topoisomerase I Inhibitors; Topotecan; Tumor Suppressor Protein p53 | 2014 |
Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
Topics: Afatinib; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Neoplasms, Experimental; Quinazolines; Real-Time Polymerase Chain Reaction; Topotecan; Xenograft Model Antitumor Assays | 2014 |
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Heterografts; Lapatinib; Mice, Nude; Mitoxantrone; Neoplasm Proteins; Neoplasm Transplantation; Quinazolines; Topotecan | 2017 |
Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Neoplasm Proteins; Quinazolines; Topotecan; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells.
Topics: Animals; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Topoisomerase Inhibitors; Topotecan | 2022 |